A common misperception exists that varicella disease is a relatively benign rite of childhood. However, approximately 5% to 10% of adults raised in the United States remain susceptible to varicella. This rate increases for immigrant populations from subtropical or tropical areas, as the incidence of infection in those areas is much lower. Despite the high rate of immunity in adults in the United States, outbreaks of varicella due to workplace exposure occur, particularly in health care settings (Lund, 1993) . This article reviews the risks of varicella infection in adults, development of varicella vaccination, and considerations for vaccination in the adult population .
EPIDEMIOLOGY OF THE VIRUS
Varicella infection is caused by the varicella-zoster virus (VZV), and is a member of the herpesvirus family. VZV primary infection commonl y is known as "chickenpox," while reactivation of the virus after primary infection is known as "shingles." Varicella infection in adults carries increased risk of morbidity and mortality. While less than 2% of reported cases occur in adults, these cases account for 25% of fatal varicella cases (Holmes, 1996) . Complic ations most likely to occur in adults are pneumonia and encephalitis. Symptoms in adults are more severe and include high fever and widespread rash.
Pregnant women carry an additional risk of complications for themselves and the fetus. Approximately 3% of babies whose mothers were infected in the first trimester will have severe fetal abnormalities (Merck, 1996) . Pregnant women are more likely to develop serious infection and deliver prematurely. If the woman is infected from 5 days prior to 2 days following delivery, the risk
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of transmission to the fetus is significant and associated with a 30% neonatal mortality rate (Merck, 1996) . Varicella infection is difficult to prevent, as it is highly communicable. The potential for the spread of VZV infection is further increased by the almost universal lack of recognition of the disease during the prodromal and most contagio us period . Recognition usually does not occur until several days of infect ivity have passed and the hallm ark rash appear s. Exposure occurs directly via contact with respiratory secretions or drainag e from the lesion s of the infected person. Exposure also occurs indirectly via contact with airborne droplets or contaminated clothing. The most common route of expo sure in workplace settings is via airborne droplet contact (Lund, 1993) .
Adult varicella infection results in significant economic loss. The amount of lost work time for an infected person may be considerable, ranging from I to 3 weeks. The employer may incur the cost of lost work time for the infected person and also for any exposed, nonimmune coworker s who remain out of work due to quarantine requirements. Workers' compensation benefits may be applicable in situation s in which coworkers develop infection. Health care costs may be substantial, particularly if employees suffer from serious complic ations. Lastly, health care employers face the additional costs and concern s regarding the potent ial for nosocomial transmission to susceptible individuals (Lund, 1993) .
DEVELOPMENT OF VARICELLA VACCINE
Prior to 1995, primary varicella prevention was not possible due to the lack of a vaccine for VZV. Short term, passive immunity was provided to those at high risk for infection following a known exposure with administration of varicella zoster immune globulin (VZIG). The efficacy of VZIG is dependent on the timing of administration in relation to exposure and must be given within 72 to 96 hours after an exposure. In some cases, VZIG is effective at preventing infection and may reduce the severity of infection in others. Due to its cost and short term efficacy, VZIG has not been appropriate for use in the general, nonimmune population .
The development of a vaccine has been attempted since the beginning of the century. A breakthrough occurred in 1971 when the virus was successfully isolated from an infected child in Japan. Researchers were able to introduce the viral isolate into guinea pig embryo cell culture to create an attenuated virus suitable for vaccination. Varicella vaccine has been available in Japan, Korea, and some European countries since 1974 (Merck, 1995) .
In the United States, the vaccine was refined by introducing the viral isolate into human cell culture and cleaning the cells to result in a biologically safe vaccine (Merck, 1995) . The vaccine was studied in clinical trials for 10 years, and on May 17, 1995 the FDA approved licensure. The vaccine is available from Merck & Company (West Point, PA) as Varivax.
VACCINE EFFICACY
Clinical trials in the United States provide varying efficacy rates depending on study protocol and the outcome used to measure efficacy. Studies using seroconversion rates that demonstrated positive antibody titers were achieved at a rate of 82% after one dose of vaccine and 94% after two doses (Holmes, 1996) . Studies using the absence of clinical infection following a known exposure to measure efficacy demonstrated somewhat lower rates. Sixty-five percent to 70% of vaccinees studied remained free from clinical infection following exposure to an infectious household contact. Those vaccinees infected had less severe infection with fewer skin lesions and without systemic symptoms.
Long term efficacy is not known for adults. Children enrolled in clinical trials exhibited a positive antibody titer for up to 6 years following vaccination (Merck, 1995) . Studies indicated there is a natural antibody boosting in response to continued exposure to wild type varicella. However, this boosting effect may be minimized in the future as vaccination rates increase and prevalence rates of wild VZV infection decrease. At present, there are no formal recommendations for additional booster doses.
Additionally, efficacy measures and determinations for boosting are somewhat limited by antibody testing issues. Antibody test sensitivity is less for antibodies acquired from vaccination than from natural infection. The most available antibody titer for varicella uses complement fixation (CF) technique and is the least sensitive and specific for VZV antibodies (Holmes, 1996) . A highly sensitive test using ELISA technique was used for vaccination studies, but is not commercially available.
VACCINE SIDE EFFECTS
Clinical trials indicated relatively few side effects from varicella vaccination. The most common side effect is local erythema and discomfort at the injection site. Additional side effects were experienced by less than 5% of vaccinees and included an injection site rash and generalized varicella like rash (Merck, 1996) . The incidence of herpes zoster after vaccination appears to be lower than that from natural infection, but these data are limited since the rate among vaccinees was followed for a NOVEMBER 1997, VOL.45, NO. 11 period of 10 years in comparison to a longer period for those with natural infection (Holmes, 1996) . Potentially, there may not be a difference in zoster incidence when comparable periods are used. Theoretically, vaccinees may shed virus following the vaccination. Viral isolate has been obtained from varicella like lesions following vaccination. One study investigated the risk of transmission by investigating siblings of vaccinated children. This study found 1% of siblings seroconverted with evidence of clinical disease following exposure to the vaccinated child (Diaz, 1991) . The risk of transmission may be higher from vaccinees who are immunocompromised. A study of immunocompromised children who developed rash after vaccination indicated a transmission rate of 17% to close nonimmune contacts based on seroconversion without evidence of clinical disease (Tsolia, 1990) . Due to the possibility of transmission, the VZV vaccine is contraindicated for those persons with close contacts at high risk of serious complications of varicella infection. Some health care employers have restricted vaccinees from caring for immunocompromised individuals following vaccination, particularly if a varicella like rash develops.
Indications and Contraindications for Varicella Vaccine

Varicella vaccination may prevent serious infection and complications for the employee and economic loss for both the employee and employer.
Varicella Vaccination
An Overview for the Occupational Health Nurse.
Loomis, S.C. (Weber, 1988) . Cost-benefit consideration in the adult population needs to be conducted to further support indications for vaccination.
CLIENT EDUCATION AND COUNSELING
Clients should receive information regarding: • Indications and contraindication s for vaccination. • Efficacy of vaccination. • Potential side effects. • Possible communicability if a post-vaccination rash develops.
Vaccinees must not take aspirin and aspirin products for 6 weeks following vaccination due to the theoretical potential for development of Reye's syndrome.
SUMMARY
The adult population nonimmune to VZV has historically remained susceptible and at risk of serious complications if infection was to occur. The recent introduction of a vaccine effective against varicella zoster virus provides a tool for primary prevention in this group. The vaccine is generally well tolerated and efficacious. The occupational health nurse should make varicella vaccination available to susceptible employees, particularly in health care settings. Varicella vaccination may prevent serious infection and complication s for the employee and economic loss for both the employee and employer.
INDICATIONS AND CONTRAINDICATIONS
The Advisory Committee on Immunization Practices of the CDC (ACIP) approved vaccination for all non-immune adults becau se of the potential for seriou s complications if infection occurs.
Prior to vaccine admini stration, an assessment of susceptibility to varicella infection should be elicited. Prevaccination titers are not recommended, as studies have indicated a history of varicella infection obtained by a skilled interviewer is highly predictive of immunity (Holmes, 1996) . General recommendations are to proceed with vaccination for those persons who provide a negative history of infection and to obtain an antibody titer for those with questionable or unknown histories.
STORAGE AND ADMINISTRATION
j / Varivax is available in single and multiple dose vials. The vaccine requires special storage. It must be stored in a -15°Celsiu s or 5°Fahrenheit frost free/freezer. The Association for Professionals in Infection Control (APIC) recommends the freezer be checked and temperature verified regularly to ensure vaccine potency. The vaccine may be stored temporaril y for up to 72 hours in a refrigerator with a temper ature between 2°and 8°Celsiu s. The vaccine is stored in a crystal form and must be reconstituted with the diluent supplied by the manufacturer. Once reconstituted, Varivax must be administered within 30 minutes.
Varivax is administered subcutaneously in a dose of 0.5 cc. Adults and adolescents older than 13 years of age should receive two doses at least 4 to 8 weeks apart.
COST-BENEFIT ANALYSIS
Cost effectiveness of varicella vaccination in adults has not been studied, possibly because this population represents a smaller target group for vaccination . The cost effectiveness of varicella vaccination in children has been studied (Lieu, 1994) . The results of this study were based on an average vaccine cost of $35.00 per dose. A cost savings of $5.40 was found for each dollar spent on vaccination when direct and indirect costs were considered . Based on what is known regarding severity of adult infection and potential for complications, the cost savings for adult vaccination is likely to be greater. This is particularly true for health care employers. A 1986 study (Weber, 1988 ) reflected a yearly cost related to varicella exposure of $55,000 for a 580 bed acute care hospital with the largest cost factor being for employee furlough 1.
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Varicella-zoster virus is highly communicable. Non-immune adults are susceptible to infection and, if infected, have increased risk of complications .
Adult varicella infection poses significant economic loss for the infected employee and potentially for exposed coworkers and the employer. Health care employers also must be concerned about transmission of varicella infection to clients.
Varicella vaccine is now available, well tolerated, and prevents infection in approximately 94% of vaccinees. The occupational health nurse needs to consider varicella vaccination for employees susceptible to infection.
